Trial Profile
Studying Interventions for Managing Patients With Chronic Myeloid Leukemia (CML)in Chronic Phase: The 5-Year Prospective Cohort Study (SIMPLICITY)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms SIMPLICITY
- Sponsors Bristol-Myers Squibb
- 13 Dec 2022 Results (At data cutoff January 28, 2020, n=810 US patients ), presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2022 Results of Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 28 Jun 2022 Status changed from active, no longer recruiting to completed.